Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Summit Stock Falls on FDA Rejection for Lung Cancer Drug
2 Cancer-Drug Developers Seeing Unusual Options Volume
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Breakfast News: Summit’s FDA Setback Isn’t the End
Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?
SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
Breakfast News: Science Strikes Back at Cancer
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Summit Expands Ivonescimab Development Into Biliary Tract Cancer
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?